3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
39
Neoplasm Metastasis
5
Metastatic Castration-resistant Prostate Cancer
3
Triple Negative Breast Neoplasms
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Thrombocytosis
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Radiosurgery
5
Androgen Antagonists
4
enzalutamide
2
Prednisone
2
Docetaxel
2
talazoparib
1
sipuleucel-T
1
rucaparib
1
olaparib
1
gallium 68 PSMA-11
1
darolutamide
1
cabazitaxel
1
apalutamide
1
XRP6258
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hematologic Tests
1
Granulocyte Colony-Stimulating Factor
1
Gonadotropin-Releasing Hormone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostate Cancer Metastatic
×
darolutamide
×
Clear all
NCT04916613
2026-04-28
GETUG-AFU 40
UNICANCER
Phase 3
Recruiting
300 enrolled